Transperineal prostate brachytherapy, using I-125 seed with or without adjuvant androgen deprivation, in patients with intermediate-risk prostate cancer: study protocol for a phase III, multicenter, randomized, controlled trial

Kenta Miki, Takayoshi Kiba, Hiroshi Sasaki, Masahito Kido, Manabu Aoki, Hiroyuki Takahashi, Keiko Miyakoda, Takushi Dokiya, Hidetoshi Yamanaka, Masanori Fukushima, Shin Egawa, Kenta Miki, Takayoshi Kiba, Hiroshi Sasaki, Masahito Kido, Manabu Aoki, Hiroyuki Takahashi, Keiko Miyakoda, Takushi Dokiya, Hidetoshi Yamanaka, Masanori Fukushima, Shin Egawa

Abstract

Background: The optimal protocol for 125I-transperineal prostatic brachytherapy (TPPB) in intermediate-risk prostate cancer (PCa) patients remains controversial. Data on the efficacy of combining androgen-deprivation therapy (ADT) with 125I-TPPB in this group remain limited and consequently the guidelines of the American Brachytherapy Society (ABS) provide no firm recommendations.

Methods/design: Seed and Hormone for Intermediate-risk Prostate Cancer (SHIP) 0804 is a phase III, multicenter, randomized, controlled study that will investigate the impact of adjuvant ADT following neoadjuvant ADT and 125I-TPPB. Prior to the end of March, 2011, a total of 420 patients with intermediate-risk, localized PCa will be enrolled and randomized to one of two treatment arms. These patients will be recruited from 20 institutions, all of which have broad experience of 125I-TPPB. Pathological slides will be centrally reviewed to confirm patient eligibility. The patients will initially undergo 3-month ADT prior to 125I-TPPB. Those randomly assigned to adjuvant therapy will subsequently undergo 9 months of adjuvant ADT. All participants will be assessed at baseline and at the following intervals: every 3 months for the first 24 months following 125I-TPPB, every 6 months during the 24- to 60-month post-125I-TPPB interval, annually between 60 and 84 months post-125I-TPPB, and on the 10th anniversary of treatment.The primary endpoint is biochemical progression-free survival (BPFS). Secondary endpoints are overall survival (OS), clinical progression-free survival, disease-specific survival, salvage therapy non-adaptive interval, acceptability (assessed using the international prostate symptom score [IPSS]), quality of life (QOL) evaluation, and adverse events. In the correlative study (SHIP36B), we also evaluate biopsy results at 36 months following treatment to examine the relationship between the results and the eventual recurrence after completion of radiotherapy.

Discussion: These two multicenter trials (SHIP0804 & SHIP36B) are expected to provide crucial data regarding the efficacy, acceptability and safety of adjuvant ADT. SHIP36B will also provide important information about the prognostic implications of PSA levels in intermediate-risk PCa patients treated with 125I-TPPB.

Trial registration: NCT00664456, NCT00898326, JUSMH-BRI-GU05-01, JUSMH-TRIGU0709.

Figures

Figure 1
Figure 1
Study design of SHIP0804 and SHIP36B. ADT, androgen deprivation therapy, TPPB, transperineal prostatic brachytherapy.

References

    1. Skinner J. Should ADT be part of care for all patients with intermediate-risk prostate cancer? Oncol News Int. 2009;18
    1. Bruner D. Subcommittee minutes-outcomes & health services research.
    1. A service of the U.S. National Institutes of Health.
    1. Saito S, Kiba T, Aoki M, Ito K, Koga H, Yamashita T, Kitagawa S, Daimon T, Dokiya T, Yamanaka H. Japanese prostate cancer outcome study of permanent I-125 seed implantation (J-POPS study): Interim results of a prospective cohort study assessing efficacy, safety and QOL. J Clin Oncol. 2008;26(May 20 supple; abstr 16137)
    1. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358(12):1250–61. doi: 10.1056/NEJMoa074311.
    1. Roach M 3rd, Hanks G, Thames H, Schellhammer P Jr, Shipley WU, Sokol GH, Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965–74.
    1. Scardino PT, Wheeler TM. Local control of prostate cancer with radiotherapy: frequency and prognostic significance of positive results of postirradiation prostate biopsy. NCI Monogr. 1988. pp. 95–103.
    1. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351(2):125–135. doi: 10.1056/NEJMoa032975.
    1. Sobin LH, Wittekind Ch, editor. UICC International Union against Cancer. TNM classification of malignant tumors. 6. John Wiley & Sons. Inc. New York; 2002. pp. 184–187.
    1. Epstein J, Allsbrook W, Amin M, Egevad L. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of prostatic carcinoma. Am J Surg Pathol. 2005;29(9):1228–42. doi: 10.1097/01.pas.0000173646.99337.b1.
    1. Nath R, Anderson LL, Luxton G, Weaver KA, Williamson JF, Meigooni AS. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine. Med Phys. 1995;22(2):209–34. doi: 10.1118/1.597458.
    1. Raben A, Chen H, Grebler A, Geltzeiler J, Geltzeiler M, Keselman I, Samlitvin, Sim S, Hanlon A, Yang J. Prostate seed implantation using 3D-Computer assisted intraoperative planning vs. a standard look-up nomogram improved target conformality with reduction in urethral and rectal wall dose. Int J Radiat Oncol Biol Phys. 2004;60(5):1631–8.
    1. Khuntia D, Reddy CA, Mahadevan A, Klein EA, Kupelian PA. Recurrence-free survival rates after external-beam radiotherapy for patients with clinical T1-T3 prostate carcinoma in the prostate-specific antigen era: what should we expect? Cancer. 2004;100(6):1283–92. doi: 10.1002/cncr.20093.
    1. Merrick GS, Butler WM, Lief JH, Galbreath RW. Five-year biochemical outcome after prostate brachytherapy for hormone-naive men < or = 62 years of age. Int J Radiat Oncol Biol Phys. 2001;50(5):1253–7.
    1. Common terminology criteria for adverse events v3.0 (CTCAE) 2006.
    1. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005;61(5):1285–90.
    1. D'Amico AV, Manola J, Loffredo M, Renshaw AA, Della-Croce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;292(7):821–7. doi: 10.1001/jama.292.7.821.
    1. Lee LN, Stock RG, Stone NN. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys. 2002;52(2):444–52.
    1. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Lief JH, Allen Z, Adamovich E. Impact of supplemental external beam radiotherapy and or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2005;61(1):32–43.
    1. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997;277(18):1445–51. doi: 10.1001/jama.277.18.1445.
    1. Naito S, Kuroiwa K, Kinukawa N, Goto K, Koga H, Ogawa O, Murai M, Shiraishi T. Clinicopathological Research Group for Localized Prostate Cancer Investigators. Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology Consensus on Gleason Grading: data from the clinicopathological research group for localized prostate cancer. J Urol. 2008;180(3):904–910. doi: 10.1016/j.juro.2008.05.047.
    1. Stone N, Potters L, Davis BJ, Ciezki JP, Zelefsky MJ, Roach M, Fearn PA, Kattan MW, Stock RG. Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes. Int J Radiat Oncol Biol Phys. 2007;69(5):1472–7.
    1. Patel AB, Waterman FM, Dicker AP. A detailed examination of the difference between planned and treated margins in 125I permanent prostate brachytherapy. Brachytherapy. 2003;2(4):223–8. doi: 10.1016/j.brachy.2003.09.002.
    1. Stone NN, Stock RG, White I, Unger P. Patterns of local failure following prostate brachytherapy. J Urol. 2007;177(5):1759–63. doi: 10.1016/j.juro.2007.01.069.
    1. Crook JM, Malone S, Perry G, Eapen L, Owen J, Robertson S, Ludgate C, Fung S, Lockwood G. Twenty-four-month postradiation prostate biopsies are strongly predictive of 7-year disease-free survival. Results from a Canadian Randomized Trial. Cancer. 2009;115(3):673–679. doi: 10.1002/cncr.24020.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj